Clinical Trials Directory

Trials / Completed

CompletedNCT03706157

Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE

Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE: a Pilot Study

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
10 (actual)
Sponsor
University Hospital, Strasbourg, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Conventional transarterial chemoembolization with Doxorubicin (c-TACE) is the gold standard treatment for Hepato Cellular Carcinoma (HCC) stage B (BCLC) / stages A and B (Child-Pugh). Clinical recommendations for cTACE indicate that the doxorubicin solution may be reconstituted in either aqueous solution or iso-osmolar ionic iodinated contrast media. There is no consensus on which solvent should be used. Hence, the clinical evaluation of Lipiodol cTACE would benefit from a standardization in the reconstitution of the drug. In this study, the comparison of the kinetics of distribution of the drug within the tumor micro-environment is expected to allow for comparison of drug solvents. This pilot study aims at evaluating the kinetics of distribution of the drug within the tumor micro-environment, for the two main solvents used in reconstituting the drug, namely normal saline and contrast media. The kinetics of distribution in the tumor will be evaluated primarily through regular biopsy sampling, and secondary with confocal laser endomicroscopy.

Conditions

Interventions

TypeNameDescription
DRUGSuper selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast mediaSuper selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media
DRUGSuper selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal salineSuper selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline

Timeline

Start date
2018-11-26
Primary completion
2019-10-09
Completion
2019-10-09
First posted
2018-10-15
Last updated
2020-07-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03706157. Inclusion in this directory is not an endorsement.